Annovis Bio, Inc. (ANVS) Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Annovis Bio, Inc. on March 26, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Malvern, PA. The report addresses a notice of non-compliance with NYSE listing standards and a change in interim financial leadership.
Key Financial Metrics
The filing provides specific data points related to the listing compliance notice but does not contain a full set of financial statements (revenue, profit, cash flow, or margins).
- 30-Day Average Market Capitalization: Approximately $37.9 million (as of March 25, 2025).
- Stockholders' Equity: $9.3 million (as of December 31, 2024).
- Compliance Thresholds: The Company failed to meet the NYSE requirement of maintaining an average market capitalization of at least $50 million and stockholders' equity of at least $50 million simultaneously.
Material Changes and Events
NYSE Delisting Notice (Item 3.01): On March 26, 2025, the Company received notice from the NYSE that it is no longer in compliance with Section 802.01B of the Listed Company Manual due to the market capitalization and equity levels noted above. Consequently, the Company's trading symbol will carry a ".BC" designation to indicate it is below continued listing criteria.
Executive Departure (Item 5.02): William Fricker, who served as Interim Chief Financial Officer since December 4, 2024, will cease serving in that role on March 27, 2025, by mutual agreement. The departure was not due to any disagreement regarding accounting or financial practices. Maria Maccecchini will continue to serve as the principal financial officer on an interim basis.
Outlook, Risks, and Management Commentary
Remediation Plan: The Company has notified the NYSE of its intent to submit a plan within 45 days to regain compliance within 18 months. The NYSE will review this plan to determine if the Company has made a reasonable demonstration of its ability to comply.
Operational Impact: Management states the notice has no immediate impact on business operations or SEC reporting obligations. The stock will continue to trade on the NYSE during the cure period, subject to plan compliance.
Risks: If the plan is not submitted timely or is not accepted, or if the Company fails to comply with the plan or meet standards by the end of the 18-month period, the NYSE will initiate suspension and delisting procedures. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of regaining compliance.
Investor Verification Checklist
- Verify the submission and acceptance of the Company's 18-month compliance plan by the NYSE within the 45-day window.
- Monitor the ".BC" trading symbol designation and any potential removal upon regaining compliance.
- Review the Company's capital raising activities or strategic actions intended to increase market capitalization and stockholders' equity.
- Confirm the appointment of a permanent Chief Financial Officer following the departure of the interim officer.
- Check for any subsequent filings regarding the status of the delisting proceedings or plan compliance reviews.